Quest Diagnostics Shares Surge on Robust 2025 Earnings and Optimistic 2026 Outlook

Quest Diagnostics (NYSE: DGX) witnessed a significant surge in its share price, climbing 6.56%, following the release of its robust fourth-quarter and full-year 2025 earnings report. The diagnostic information services provider announced substantial growth in both revenue and earnings per share (EPS) for the fiscal year 2025, surpassing market expectations. Furthermore, the company provided an optimistic outlook for 2026, projecting continued expansion across its top and bottom lines. This strong performance is attributed to resilient demand for diagnostic testing services and the successful execution of strategic initiatives. Investors reacted positively to the impressive financial results and the confident future guidance, signaling strong market confidence in the company's trajectory.